Outlook Therapeutics (FRA:41O) Change In Payables And Accrued Expense : €2.95 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Change In Payables And Accrued Expense?

Outlook Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €-5.20 Mil. It means Outlook Therapeutics's Accounts Payable & Accrued Expense declined by €5.20 Mil from Dec. 2024 to Mar. 2025 .

Outlook Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2024 was €1.70 Mil. It means Outlook Therapeutics's Accounts Payable & Accrued Expense increased by €1.70 Mil from Sep. 2023 to Sep. 2024 .

Outlook Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Outlook Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Change In Payables And Accrued Expense Chart

Outlook Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.65

-4.67

1.47

2.22

1.70

Outlook Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.67	1.19	2.78	4.18	-5.20

Outlook Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.95 Mil.

Outlook Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

OTLK:USA 41O:Germany

Address

111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines